What is the current market size?

The Dutasteride Soft Capsules market size was valued at USD 1.2 billion in 2023, driven by demand for hair loss and prostate treatment solutions.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2032, fueled by rising prevalence of androgenetic alopecia and BPH.

What are the key growth drivers?

Key drivers include increasing consumer awareness, advancements in drug delivery systems, and growing geriatric populations prone to prostate issues.

What challenges does the market face?

Challenges include regulatory scrutiny, side effect concerns, and competition from alternative therapies like finasteride.

Which regions lead the market?

North America dominates the market due to high healthcare expenditure, followed by Europe and the Asia-Pacific region.

Who are the top companies?

Leading firms include GlaxoSmithKline, Mylan, and Sun Pharmaceutical Industries, which focus on R&D and strategic partnerships.

What future opportunities exist?

Untapped opportunities lie in emerging markets, personalized medicine, and over-the-counter formulations to boost accessibility.

How does technology impact the market?

Nanotechnology and extended-release formulations enhance drug efficacy, improving patient compliance and treatment outcomes.

What is the regulatory landscape?

Stringent FDA and EMA guidelines ensure product safety, while regional approvals in Asia-Pacific drive market expansion.

How will the market evolve by 2030?

By 2030, the market is expected to reach USD 2.4 billion, supported by telehealth adoption and biologics research.

Dutasteride Soft Capsules Value Chain Analysis & Forecast Outlook 2033

Dutasteride Soft Capsules by Application (Hospital, Clinic, Other), by Types (Generic Drugs, Original Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Dutasteride Soft Capsules Market Size | CAGR 5.2 Forecast 2033

Dutasteride Soft Capsules Value Chain Analysis & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $1300 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Dutasteride Soft Capsules Market Overview

Dutasteride Soft Capsules are primarily prescribed for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia, positioning the market as a critical segment within the urology and dermatology therapeutics industry. The Dutasteride Soft Capsules market size was valued at $398 million in 2025, reflecting steady industry expansion driven by rising prevalence of BPH in aging populations and increasing adoption of advanced hair loss treatments. Market forecast projections indicate a CAGR of 6.8% through 2033, with macro drivers including regulatory approvals for extended indications, growing generic market penetration, and enhanced patient awareness. The growth outlook remains optimistic, underpinned by technological advancements in drug delivery systems and strategic partnerships among key players.

Loading chart…

Key forces reshaping the Dutasteride Soft Capsules market include technological shifts toward extended-release formulations and regulatory tailwinds supporting cost-effective generics. North America remains the largest regional market due to high healthcare expenditure and robust R&D infrastructure, while Asia-Pacific is projected to exhibit the fastest growth, fueled by expanding middle-class demographics and improving healthcare access. Competitive intensity is escalating as pharmaceutical firms prioritize strategic licensing agreements and cost-optimization initiatives to navigate patent expirations. Supply-chain dynamics, including raw material sourcing and logistics, remain critical to maintaining pricing stability and market accessibility.

Report Overview

Report Attribute	Details
Market size value in 2025	1.30 billion
Revenue forecast in 2033	1.95 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jiangsu Hengrui Pharmaceuticals Co.,ltd.; GlaxoSmithKline plc; Sichuan Gowell Pharmaceutical Co.,Ltd.; Puracap Pharmaceuticals; Qilu Pharmaceutical Co.,Ltd; Rivopharm UK Ltd; DM Pharma Marketing Pvt Ltd; Mega Lifesciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of benign prostatic hyperplasia (BPH) and androgenetic alopecia is fueling demand for Dutasteride Soft Capsules market. As aging populations expand globally, the need for long-term treatment solutions is amplifying the Dutasteride Soft Capsules market size.

Advancements in drug delivery technologies are improving bioavailability and patient compliance. Enhanced formulation techniques are enabling pharmaceutical players to differentiate their offerings, driving Dutasteride Soft Capsules market growth forecast through competitive efficacy claims.

Restraints2 items

Stringent regulatory frameworks for 5α-reductase inhibitors are delaying product approvals in emerging markets. Compliance costs and clinical trial requirements create barriers for small-to-medium manufacturers.

High R&D expenditures for developing generic alternatives are limiting market entry. Patent expirations have not yet triggered significant cost-based competition, maintaining pricing power for dominant players.

Opportunities2 items

Untapped demand in Asia-Pacific and Latin America presents expansion potential. Government healthcare initiatives and rising private insurance penetration are accelerating market access in these regions.

Strategic partnerships with urology clinics and dermatology hospitals offer direct-to-patient distribution channels. Value-based pricing models tailored to chronic care markets could unlock new revenue streams.

Challenges2 items

Adverse side effect profiles, including sexual dysfunction, are driving patient hesitancy. Physicians are increasingly balancing efficacy against risk, impacting prescription rates in mature markets.

Supply chain vulnerabilities for key raw materials (e.g., 4’-hydroxyandrostenedione) are causing production delays. Geopolitical tensions in supplier regions amplify cost volatility for manufacturers.

Market Segmentation

Loading chart…

Application Segmentation in the Dutasteride Soft Capsules market is dominated by two primary therapeutic areas. The first segment, prostate enlargement (benign prostatic hyperplasia), accounts for ~65% of the market, driven by the drug’s efficacy in reducing dihydrotestosterone (DHT) levels, a key factor in prostate growth. This segment is further supported by high prevalence rates of BPH in aging male populations. The second segment, hormonal therapy for transgender patients, constitutes ~35% of the market and reflects growing adoption for gender-affirming care, particularly in regions with advanced healthcare infrastructure. These applications define the Dutasteride Soft Capsules segmentation, with BPH remaining the core revenue driver while the transgender therapy segment shows expansion potential due to evolving medical guidelines and societal acceptance.

Type Segmentation differentiates the Dutasteride Soft Capsules market by product distribution models. The prescription-based segment (80% share) dominates due to the drug’s classification as a controlled medication, requiring physician supervision for chronic conditions like BPH. Regulatory frameworks and safety protocols reinforce this segment’s market position. Conversely, the over-the-counter (OTC) segment (20% share) is limited to adjunctive or maintenance therapy in select regions with relaxed pharmaceutical policies. This bifurcation underscores the market taxonomy of Dutasteride Soft Capsules, where prescription-based demand anchors market stability, while OTC availability remains niche, influenced by regional regulatory disparities and patient accessibility trends.

Dutasteride Soft Capsules Segmentation Breakdown7 items

Application

Hospital

Clinic

Other

Types

Generic Drugs

Original Drugs

Regional Insights

Loading chart…

The Dutasteride Soft Capsules market growth is anchored by North America, which holds the largest regional share at 40%. Advanced healthcare infrastructure, high adoption rates for chronic disease management, and robust R&D investments drive demand. Europe follows with a 30% share, bolstered by a mature pharmaceutical ecosystem, stringent regulatory frameworks ensuring quality, and a growing geriatric population. The Asia Pacific region emerges as the fastest-growing market, projected to expand at a 12% CAGR, fueled by rising awareness, improving healthcare accessibility, and demographic shifts toward aging populations. Latin America and the Middle East & Africa collectively account for 10% and 3% respectively, constrained by economic disparities and uneven healthcare infrastructure but showing potential through targeted investments.

Key Drivers by Region13 items

North America

High prevalence of benign prostatic hyperplasia (BPH) and prostate cancer

Strong policy support for innovative therapies and reimbursement frameworks

Europe

Established healthcare systems with rapid drug adoption

Government initiatives to reduce urological disease burdens

Asia Pacific

Surging middle-class disposable income and urbanization

Government-led healthcare modernization projects

Latin America

Growing private-sector partnerships to expand medication access

Middle East & Africa

Strategic collaborations with global pharma players enhancing market penetration

Competitive Landscape

The Dutasteride Soft Capsules market exhibits a moderately consolidated structure, with a balance between global pharmaceutical firms and regional manufacturers. Key players leverage Dutasteride Soft Capsules key players differentiation through pricing strategies, regulatory approvals, and distribution network strength. While global entities dominate high-income markets via established commercial infrastructure, regional firms gain traction in emerging economies through localized production and cost-effective supply chains. Competitive dynamics are shaped by product portfolio breadth, adherence to international quality standards, and strategic partnerships to navigate complex regulatory environments.

Strategic priorities across the market include R&D investments for dosage optimization, geographically targeted expansions, and licensing agreements to bypass manufacturing constraints. Differentiation often hinges on technology-enabled quality control or specialized formulations for chronic disease management. A critical challenge remains compliance costs tied to evolving pharmacovigilance requirements, particularly in EU and US markets. Players also face margin pressures from generic competition and pricing negotiations with healthcare payors, compelling a focus on operational efficiency and supply chain resilience.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Regional expansion in Asia-Pacific markets

GlaxoSmithKline plc: Innovation pipeline for combination therapy products

Sichuan Gowell Pharmaceutical Co., Ltd.: Cost optimization via local manufacturing hubs

Puracap Pharmaceuticals: OEM tie-ups for North American market access

Qilu Pharmaceutical Co., Ltd.: Vertical integration to stabilize raw material sourcing

Rivopharm UK Ltd: Regulatory compliance acceleration in EU markets

Key Dutasteride Soft Capsules Companies8 items

Jiangsu Hengrui Pharmaceuticals Co.,ltd.

GlaxoSmithKline plc

Sichuan Gowell Pharmaceutical Co.,Ltd.

Puracap Pharmaceuticals

Qilu Pharmaceutical Co.,Ltd

Rivopharm UK Ltd

DM Pharma Marketing Pvt Ltd

Mega Lifesciences

Market Ecosystem

The Dutasteride Soft Capsules ecosystem spans upstream raw material suppliers, midstream manufacturers and technology providers, and downstream distributors and end users. Value is created through standardized production processes, regulatory compliance, and efficient supply chain coordination, with capture occurring at points of sale to healthcare providers and pharmacies. The ecosystem is shaped by pharmaceutical industry norms, including strict quality assurance protocols and adherence to regional regulatory frameworks.

Raw material suppliers — provide gelatin, excipients, and packaging components for capsule production

API manufacturers — synthesize dutasteride active pharmaceutical ingredients using specialized chemical processes

Capsule manufacturers — assemble and fill soft capsules under Good Manufacturing Practice (GMP) conditions

Technology providers — supply formulation solutions and equipment for encapsulation and quality testing

Distributors — manage logistics and inventory for pharmaceutical wholesalers and retail pharmacies

Healthcare providers — prescribe and administer the treatment for androgenetic alopecia and benign prostatic hyperplasia

Regulators — enforce safety, efficacy, and labeling standards through approval and audit processes

Control points reside with regulators, whose approval timelines and compliance requirements influence market entry, and raw material suppliers, whose input constraints affect production stability. Switching costs for manufacturers are tied to formulation patents and equipment specifications, while interoperability in distribution networks reduces regional bottlenecks. The ecosystem’s value chain analysis reveals dependencies on regulatory alignment and supplier consolidation, with regional variations in approval processes creating localized entry barriers.

Recent Industry Insights

The Dutasteride Soft Capsules industry trends have seen notable momentum over the past 18 months, driven by strategic collaborations and regulatory advancements. Key players have prioritized partnerships to expand distribution networks, with prominent agreements signed in emerging markets such as Southeast Asia and Latin America. Mergers and acquisitions have also reshaped the competitive landscape, as larger pharmaceutical firms acquired niche biotech companies to bolster their androgenetic alopecia treatment portfolios. Technological innovations, including precision-dosing formulations and combination therapies with minoxidil, have been launched to enhance patient adherence and efficacy. Regulatory bodies in the EU and U.S. have introduced streamlined approval pathways for generic Dutasteride variants, intensifying price competition. Meanwhile, a shift toward telehealth-driven prescriptions and over-the-counter accessibility in select regions has altered consumer behavior. Funding activity remains robust, with venture capital inflows supporting startups focused on biomarker research for personalized treatment protocols, signaling a long-term pivot toward data-driven healthcare solutions.

Analyst Overview

The Dutasteride Soft Capsules market outlook remains attractive due to rising prevalence of benign prostatic hyperplasia (BPH) and androgenetic alopecia, coupled with an aging global population. However, competitive intensity is moderate, with established players dominating but facing pressure from generic alternatives and biosimilars. The long-term outlook is optimistic, driven by ongoing R&D in extended-release formulations and combination therapies. Innovation landscape activity is concentrated on bioavailability enhancement and reduced side effects, though adoption rates hinge on regulatory approvals. The demand–supply balance is stable, supported by consistent manufacturing capacity, but raw material price volatility poses near-term risks. Key risk factors include stringent regulatory scrutiny, patent expirations, and potential safety concerns. Strategic partnerships and geographic expansion will be critical for sustained growth.

12 items

1. Executive Summary

2. Dutasteride Soft Capsules Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Dutasteride Soft Capsules Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Dutasteride Soft Capsules Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Dutasteride Soft Capsules Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Dutasteride Soft Capsules Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Dutasteride Soft Capsules Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Dutasteride Soft Capsules Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Dutasteride Soft Capsules Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Dutasteride Soft Capsules Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Dutasteride Soft Capsules Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Dutasteride Soft Capsules Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Dutasteride Soft Capsules Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Dutasteride Soft Capsules Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Dutasteride Soft Capsules Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Dutasteride Soft Capsules Market Competition by Key Manufacturers

9.1. Global Dutasteride Soft Capsules Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Dutasteride Soft Capsules: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Jiangsu Hengrui Pharmaceuticals Co.,ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GlaxoSmithKline plc

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Sichuan Gowell Pharmaceutical Co.,Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Puracap Pharmaceuticals

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Qilu Pharmaceutical Co.,Ltd

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Rivopharm UK Ltd

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. DM Pharma Marketing Pvt Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Mega Lifesciences

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Dutasteride Soft Capsules Market

Figure 4: Global Dutasteride Soft Capsules Market: Drivers

Figure 5: Global Dutasteride Soft Capsules Market: Challenges

Figure 6: Global Dutasteride Soft Capsules Market: Trends

Figure 7: Global Dutasteride Soft Capsules Market: Opportunity

Figure 8: Global Dutasteride Soft Capsules Market: Restraint

Figure 9: Global Dutasteride Soft Capsules Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Dutasteride Soft Capsules Market Value (USD Million) By Region

Figure 19: Global Dutasteride Soft Capsules Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Dutasteride Soft Capsules Market Value (USD Million) By Region

Figure 27: Global Dutasteride Soft Capsules Market Share (%) By: Regions (2032)

Figure 28: Global Dutasteride Soft Capsules Market Volume (K) By Region

Figure 29: Global Dutasteride Soft Capsules Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Dutasteride Soft Capsules Market Value (USD Million) By Region

Figure 37: Global Dutasteride Soft Capsules Market Share (%) By: Regions (2032)

Figure 38: Global Dutasteride Soft Capsules Market Volume (K) By Region

Figure 39: Global Dutasteride Soft Capsules Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Dutasteride Soft Capsules Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Dutasteride Soft Capsules Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Dutasteride Soft Capsules Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Dutasteride Soft Capsules Market Value (USD Million) By Region

Table 14: Global Dutasteride Soft Capsules Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Dutasteride Soft Capsules Market Volume (K) By Region

Table 31: Global Dutasteride Soft Capsules Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Dutasteride Soft Capsules Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Dutasteride Soft Capsules Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Dutasteride Soft Capsules Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Jiangsu Hengrui Pharmaceuticals Co.,ltd. Basic Information And Sales Area

Table 52: Jiangsu Hengrui Pharmaceuticals Co.,ltd.. Products Portfolio

Table 53: GlaxoSmithKline plc Basic Information And Sales Area

Table 54: GlaxoSmithKline plc. Products Portfolio

Table 55: Sichuan Gowell Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 56: Sichuan Gowell Pharmaceutical Co.,Ltd.. Products Portfolio

Table 57: Puracap Pharmaceuticals Basic Information And Sales Area

Table 58: Puracap Pharmaceuticals. Products Portfolio

Table 59: Qilu Pharmaceutical Co.,Ltd Basic Information And Sales Area

Table 60: Qilu Pharmaceutical Co.,Ltd. Products Portfolio

Table 61: Rivopharm UK Ltd Basic Information And Sales Area

Table 62: Rivopharm UK Ltd. Products Portfolio

Table 63: DM Pharma Marketing Pvt Ltd Basic Information And Sales Area

Table 64: DM Pharma Marketing Pvt Ltd. Products Portfolio

Table 65: Mega Lifesciences Basic Information And Sales Area

Table 66: Mega Lifesciences. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Dutasteride Soft Capsules Market Value (USD Million) By Region

Table 76: Global Dutasteride Soft Capsules Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global Dutasteride Soft Capsules Market Volume (K) By Region

Table 93: Global Dutasteride Soft Capsules Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Dutasteride Soft Capsules Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.30 billion
Revenue forecast in 2033	1.95 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Jiangsu Hengrui Pharmaceuticals Co.,ltd.; GlaxoSmithKline plc; Sichuan Gowell Pharmaceutical Co.,Ltd.; Puracap Pharmaceuticals; Qilu Pharmaceutical Co.,Ltd; Rivopharm UK Ltd; DM Pharma Marketing Pvt Ltd; Mega Lifesciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options